Featuring Matthew Shair, Professor of Chemistry & Chemical Biology, Harvard University
The Path to the Clinic
Professor Shair studies human disease biology using small molecules and translates these studies towards novel therapeutics. His molecules to treat AML were recently licensed by Merck for clinical development. He has been a founder of several biotech companies including Infinity Pharmaceuticals, Makoto Life Sciences and Chemiderm, and an advisor to several others.
This event is primarily intended for Harvard University faculty, postdoctoral researchers, and graduate students who are interested in learning about technology commercialization, careers outside of academia, and scientific entrepreneurship. However, the event is open to all.
View a map of the building location: http://map.harvard.edu/?bld=04240&level=9